Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 176

1.

Variants at HLA-A, HLA-C, and HLA-DQB1 confer risk of psoriasis vulgaris in Japanese.

Hirata J, Hirota T, Ozeki T, Kanai M, Sudo T, Tanaka T, Hizawa N, Nakagawa H, Sato S, Mushiroda T, Saeki H, Tamari M, Okada Y.

J Invest Dermatol. 2017 Oct 12. pii: S0022-202X(17)33037-3. doi: 10.1016/j.jid.2017.10.001. [Epub ahead of print]

PMID:
29031612
2.

Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption.

Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G, Nagase H, Miyaura C, Inada M.

FEBS Open Bio. 2017 Jul 20;7(8):1178-1185. doi: 10.1002/2211-5463.12258. eCollection 2017 Aug.

3.

Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.

Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Aoyama T, Soyama H, Goto T, Hirata J, Suzuki A, Sasa H, Nagaoka I, Tsuda H, Furuya K.

Cancer Chemother Pharmacol. 2017 Jul 19. doi: 10.1007/s00280-017-3395-5. [Epub ahead of print]

PMID:
28726081
4.

Future Directions of Genomics Research in Rheumatic Diseases.

Okada Y, Kishikawa T, Sakaue S, Hirata J.

Rheum Dis Clin North Am. 2017 Aug;43(3):481-487. doi: 10.1016/j.rdc.2017.04.009. Review.

PMID:
28711147
5.

Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.

Shibutani T, Takano M, Miyamoto M, Yoshikawa T, Aoyama T, Soyama H, Hirata J, Suzuki A, Sasa H, Furuya K.

Mol Clin Oncol. 2017 Jul;7(1):51-55. doi: 10.3892/mco.2017.1258. Epub 2017 May 12.

6.

Factors favouring long-term survival following recurrence in ovarian cancer.

Soyama H, Takano M, Miyamoto M, Yoshikawa T, Aoyama T, Goto T, Hirata J, Suzuki A, Sasa H, Furuya K.

Mol Clin Oncol. 2017 Jul;7(1):42-46. doi: 10.3892/mco.2017.1266. Epub 2017 May 17.

7.

Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.

Lu D, Gillespie WR, Girish S, Agarwal P, Li C, Hirata J, Chu YW, Kagedal M, Leon L, Maiya V, Jin JY.

CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):401-408. doi: 10.1002/psp4.12192. Epub 2017 May 23.

8.

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.

Miyamoto M, Takano M, Tsuda H, Soyama H, Aoyama T, Ishibashi H, Kato K, Iwahashi H, Matuura H, Yoshikawa T, Suzuki A, Hirata J, Furuya K.

Oncology. 2017;93(1):29-35. doi: 10.1159/000459625. Epub 2017 Mar 4.

9.

Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.

Lu D, Gibiansky L, Agarwal P, Dere RC, Li C, Chu YW, Hirata J, Joshi A, Jin JY, Girish S.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):665-673. doi: 10.1002/psp4.12137. Epub 2016 Nov 10.

10.

Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Kato M, Takano M, Miyamoto M, Sasaki N, Goto T, Suzuki A, Hirata J, Sasa H, Tsuda H, Furuya K.

Mol Clin Oncol. 2016 Oct;5(4):395-401. Epub 2016 Aug 2.

11.

Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis.

Okada Y, Suzuki A, Ikari K, Terao C, Kochi Y, Ohmura K, Higasa K, Akiyama M, Ashikawa K, Kanai M, Hirata J, Suita N, Teo YY, Xu H, Bae SC, Takahashi A, Momozawa Y, Matsuda K, Momohara S, Taniguchi A, Yamada R, Mimori T, Kubo M, Brown MA, Raychaudhuri S, Matsuda F, Yamanaka H, Kamatani Y, Yamamoto K.

Am J Hum Genet. 2016 Aug 4;99(2):366-74. doi: 10.1016/j.ajhg.2016.06.019.

12.

Corrigendum: Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis.

Taniguchi T, Miyauchi E, Nakamura S, Hirai M, Suzue K, Imai T, Nomura T, Handa T, Okada H, Shimokawa C, Onishi R, Olia A, Hirata J, Tomita H, Ohno H, Horii T, Hisaeda H.

Sci Rep. 2016 Jan 7;6:17248. doi: 10.1038/srep17248. No abstract available.

13.

Activation of aryl hydrocarbon receptor mediates suppression of hypoxia-inducible factor-dependent erythropoietin expression by indoxyl sulfate.

Asai H, Hirata J, Hirano A, Hirai K, Seki S, Watanabe-Akanuma M.

Am J Physiol Cell Physiol. 2016 Jan 15;310(2):C142-50. doi: 10.1152/ajpcell.00172.2015. Epub 2015 Nov 11.

14.

Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis.

Taniguchi T, Miyauchi E, Nakamura S, Hirai M, Suzue K, Imai T, Nomura T, Handa T, Okada H, Shimokawa C, Onishi R, Olia A, Hirata J, Tomita H, Ohno H, Horii T, Hisaeda H.

Sci Rep. 2015 Oct 27;5:15699. doi: 10.1038/srep15699. Erratum in: Sci Rep. 2016;6:17248.

15.

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP.

Blood. 2016 Jan 7;127(1):79-86. doi: 10.1182/blood-2015-03-634394. Epub 2015 Oct 15.

16.

A transient resistance to blood-stage malaria in interferon-γ-deficient mice through impaired production of the host cells preferred by malaria parasites.

Okada H, Suzue K, Imai T, Taniguchi T, Shimokawa C, Onishi R, Hirata J, Hisaeda H.

Front Microbiol. 2015 Jun 17;6:600. doi: 10.3389/fmicb.2015.00600. eCollection 2015.

17.

Indoxyl sulfate exacerbates low bone turnover induced by parathyroidectomy in young adult rats.

Hirata J, Hirai K, Asai H, Matsumoto C, Inada M, Miyaura C, Yamato H, Watanabe-Akanuma M.

Bone. 2015 Oct;79:252-8. doi: 10.1016/j.bone.2015.06.010. Epub 2015 Jun 23.

PMID:
26112820
18.

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ.

Blood. 2015 Apr 30;125(18):2779-85. doi: 10.1182/blood-2014-12-613570. Epub 2015 Mar 13.

19.

A Japanese case of cerebellar ataxia, spastic paraparesis and deep sensory impairment associated with a novel homozygous TTC19 mutation.

Kunii M, Doi H, Higashiyama Y, Kugimoto C, Ueda N, Hirata J, Tomita-Katsumoto A, Kashikura-Kojima M, Kubota S, Taniguchi M, Murayama K, Nakashima M, Tsurusaki Y, Miyake N, Saitsu H, Matsumoto N, Tanaka F.

J Hum Genet. 2015 Apr;60(4):187-91. doi: 10.1038/jhg.2015.7. Epub 2015 Feb 5. Review.

PMID:
25652355
20.

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

Miyamoto M, Takano M, Iwaya K, Shinomiya N, Goto T, Kato M, Suzuki A, Aoyama T, Hirata J, Nagaoka I, Tsuda H, Furuya K.

Br J Cancer. 2015 Feb 17;112(4):739-44. doi: 10.1038/bjc.2015.1. Epub 2015 Jan 27.

Supplemental Content

Loading ...
Support Center